Dutcher, 2013 - Google Patents
Recent developments in the treatment of renal cell carcinomaDutcher, 2013
View HTML- Document ID
- 12419881846145073666
- Author
- Dutcher J
- Publication year
- Publication venue
- Therapeutic advances in urology
External Links
Snippet
Renal cell carcinoma (RCC) management has been imbued with new interest, in large part due to the recent success of new treatment options for advanced and metastatic disease. This has also been accompanied by less generally well known advances in the …
- 208000006265 Renal Cell Carcinoma 0 title abstract description 98
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dutcher | Recent developments in the treatment of renal cell carcinoma | |
Isaacsson Velho et al. | PD-1/PD-L1 pathway inhibitors in advanced prostate cancer | |
Gaudreau et al. | Neoadjuvant chemotherapy increases cytotoxic T cell, tissue resident memory T cell, and B cell infiltration in resectable NSCLC | |
Qu et al. | The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer | |
Ganesh et al. | Immunotherapy in colorectal cancer: rationale, challenges and potential | |
Osa et al. | Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients | |
Gide et al. | Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma | |
Ben‐Ami et al. | Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study | |
Chocarro de Erauso et al. | Resistance to PD-L1/PD-1 blockade immunotherapy. A tumor-intrinsic or tumor-extrinsic phenomenon? | |
Atkins et al. | Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives | |
Weinstock et al. | Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma | |
Packer et al. | Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference | |
Smith et al. | Nivolumab for the treatment of colorectal cancer | |
Ficial et al. | Expression of T-cell exhaustion molecules and human endogenous retroviruses as predictive biomarkers for response to nivolumab in metastatic clear cell renal cell carcinoma | |
Le Du et al. | Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? | |
Mina et al. | Immunotherapy for the treatment of breast cancer: emerging new data | |
Lim et al. | Pembrolizumab for the treatment of non-small cell lung cancer | |
Khattak et al. | Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm | |
Ciccarese et al. | New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors | |
Lerner et al. | Summary and recommendations from the National Cancer Institute’s clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer | |
Mantia et al. | Vascular endothelial growth factor and programmed death‐1 pathway inhibitors in renal cell carcinoma | |
Rihawi et al. | Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence | |
Ninomiya et al. | Pembrolizumab for the first-line treatment of non-small cell lung cancer | |
Shen et al. | Highlights on immune checkpoint inhibitors in non–small cell lung cancer | |
Alaia et al. | Ipilimumab for the treatment of metastatic prostate cancer |